Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Retina Macula Institute (RMI) is a specialized medical practice and clinical research center focused on the diagnosis and treatment of complex vitreoretinal and macular diseases. Founded in 2007 by Dr. Ron P. Gallemore, the institute operates state-of-the-art facilities in Torrance and Los Angeles, California. RMI provides advanced patient care, including intravitreal injections, photodynamic therapy, and complex retinal surgery. Additionally, the institute is a prominent clinical research site, participating in numerous Phase 1 through Phase 3 clinical trials for innovative ophthalmic therapies. These trials target conditions such as age-related macular degeneration, diabetic retinopathy, and geographic atrophy. With a commitment to both compassionate care and scientific advancement, RMI serves as a critical hub for retinal health in Southern California.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Retina Macula Institute.